DPTX3186 in Wnt Pathway Activated Solid Tumors

Open to people ages 18 years and up

• Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
• At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
• ECOG performance status of 0 or 1.
• Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
• Age ≥18 years (or ≥ age of majority per local regulation)
• Life expectancy ≥3 months
• Willing and able to comply with protocol requirements

• Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
• Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
• Inadequate organ function
• Known hypersensitivity to study drug or excipients
• Known history of human immunodeficiency virus (HIV) infection.
• Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C (HCV) infection viral load.